[Bone metastasis in prostate cancer]

Moltzahn, F; Thalmann, G N (2012). [Bone metastasis in prostate cancer]. Urologe, 51(1), pp. 20-6. Berlin: Springer-Verlag 10.1007/s00120-011-2741-1

[img]
Preview
Text
120_2011_Article_2741.pdf - Published Version
Available under License Publisher holds Copyright.

Download (400kB) | Preview

Bone metastasis and skeletal complications have a devastating impact on the quality of life and are a major cause of morbidity in prostate cancer patients. In addition to established bone-targeted therapies, new drugs such as endothelin A receptor antagonists, MET and VEGFR-2 antagonists or radiopharmaceuticals are in the focus of development. The standard care in prostate cancer patients with bone metastases to prevent skeletal-related events (SRE) are bisphosphonates. Denosumab, a human monoclonal antibody against RANKL, appeared to be superior to zoledronic acid for prevention of SRE and has been shown to prolong bone metastases-free survival. In contrast to zoledronic acid, denosumab clearance is not dependent on kidney function and can be administered subcutaneously. Similar rates of toxicity were observed for both substances; however, long-term data for denosumab are limited.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Moltzahn, Felix Roman, Thalmann, George

ISSN:

0340-2592

Publisher:

Springer-Verlag

Language:

German

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:38

Last Modified:

05 Dec 2022 14:12

Publisher DOI:

10.1007/s00120-011-2741-1

PubMed ID:

22258372

Web of Science ID:

000300320700004

BORIS DOI:

10.7892/boris.15439

URI:

https://boris.unibe.ch/id/eprint/15439 (FactScience: 222784)

Actions (login required)

Edit item Edit item
Provide Feedback